{"entity":{"id":"nct05304377","kind":"trial","name":"A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia","aka":[],"tldr":"A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.","summary":"A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia is a phase 1 interventional study registered as NCT05304377 by Enliven Therapeutics, with 250 participants planned, started 2022-05-22. Conditions recorded: Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive and Cml. Interventions recorded: ELVN-001.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05304377","url":"https://clinicaltrials.gov/study/NCT05304377"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","cml"],"sections":[],"technologies":[],"targets":[],"drugs":["relcobatinib"],"companies":["enliven-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05304377","phase":"1","setting":"A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia","sponsor":"Enliven Therapeutics","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05304377/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"relcobatinib","kind":"drug","name":"Relcobatinib","route":"/drugs/relcobatinib/"}],"company":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/"}]}}